Latest Business and People News
Updated employee announcements, business news, awards and recognition in the industry today.
People NewsOmniComm Systems announced that current president and Chief Operating Officer, Stephen Johnson, will be name Chief Executive Officer in place of current CEO Cornelius Wilt. Wilt will remain with the company as Executive Chairman. Additionally, OmniComm Head of Development, Keith Howells will be named as Chief Technology Officer in place of company founder, Chairman of the Board and current CTO Randall Smith. Smith will also remain with the company as Executive Vice Chairman.
Industry veteran George Masoura has joined Drug Dev as Vice President, Business Development, Europe.
ClinActis announced Bill Van Nostrand as Head of Business Development, North America. Van Nostrand is the founder of late-stage CRO, InVivo.
TFS has appointed Dr. Bassem Saleh as Chief Medical Officer and Ed Tumaian as VP Global Clinical Development. Saleh and Tumaian will both also join the Operational Leadership Team.
Worldwide Clinical Trials has appointed William Hirschman as Executive Vice President and Head of Global Business Development.
INC Research has appointed the following experts to their Real World & Late Phase and Global Consulting teams: Dr. James Featherstone as Senior Vice President of Strategy Consulting, Janet Baldwin as Vice President of Real World & Late Phase and Head of North America Operations, Nathalie Doize as Vice President, Real World & Late Phase and Head of Europe and Asia/Pacific Operations and Alastair MacDonald as Executive Director, Real World & Late Phase.
RecognitionRho announced that Jack Modell, MD, Vice President and Senior Medical Officer, was named as a board member for the Carolinas Chapter of the National Diversity Council (NDC). The NDC is a national non-partisan nonprofit organization dedicated to providing resources and advocacy for the value of diversity and inclusion.
ERT has received the Omega Management Group Corporation’s NorthFace ScoreBoard (NFSB) Award for achieving excellence in customer satisfaction for the fifth consecutive year.
goBalto has been selected by CIOReview as one of the 20 Most Promising Biotech Technology Solution Providers for the second consecutive year.
The International Society for CNS Drug Development (ISCDD) celebrated its 15th anniversary at the ISCDD 2017 Annual Meeting.
Rho has been named as a winner in the inaugural Corporate Philanthropy Awards by the Triangle Business Journal.
ICON plc has been awarded “Best Clinical Research Organization” at the Vaccine Industry Excellence Awards.
SimpleTrials has been recognized as one of the Top 10 eClinical Trial Management Solution Providers for 2017 by Pharma Tech Outlook Magazine.
Business NewsDrug Dev expanded the adoptions of its DrugDev Spark clinical operations suite in Europe.
Drug Dev announces an industry milestone of over $2 billion processed to sites on behalf of sponsors and CROs worldwide.
ACI Clinical has surpassed a new milestone of 50,000 adjudicated endpoints during the first quarter of 2017.
BioPlan Associates has released its updated textbook, A Quick Guide to Clinical Trials, 2nd Edition, which describes the clinical trials process and drug development from an international perspective.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
